Minireviews
Copyright ©The Author(s) 2022.
World J Cardiol. Jan 26, 2022; 14(1): 40-53
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.40
Table 6 Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes 8: Comparison to Organization to Assess Strategies in Ischemic Syndromes 5 major bleeding (< 48 h of percutaneous coronary intervention)
Adjusted major bleeding rateOASIS 5 PCI
OASIS 5 PCI
Fondaparinux
Enoxaparin
Major bleeding
Major bleeding
FUTURA 1.5% 3.6%
Standard dose UFH 1.1% (0.6-2.1)
FUTURA
Low dose UFH 1.2% (0.6-2.2)
PCI: Percutaneous coronary intervention; FUTURA: Fondaparinux with unfractionated heparin; OASIS: Organization to Assess Strategies in Ischemic Syndromes; UFH: Unfractionated heparin.